RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

Chunyan Gu; Ting Lu; Wang Wang; Miaomiao Shao; Rongfang Wei; Mengjie Guo; Rui Li; Li Qiao; Ye Hu; Fenghuang Zhan; Anja Seckinger; Dirk Hose; Ye Yang

doi:10.1038/s41375-020-01033-z

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

Leukemia. 2021 Jun;35(6):1803-1807. doi: 10.1038/s41375-020-01033-z. Epub 2020 Sep 8.

Authors

Chunyan Gu^#^{1

2

3}, Ting Lu^#², Wang Wang^{1

2

3}, Miaomiao Shao², Rongfang Wei^{1

2

3}, Mengjie Guo^{1

2

3}, Rui Li^{1

2

3}, Li Qiao^{1

2

3}, Ye Hu², Fenghuang Zhan⁴, Anja Seckinger⁵, Dirk Hose⁵, Ye Yang^{6

7

8

9}

Affiliations

¹ The Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
² School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
³ Key Laboratory for Combination of Acupuncture and Chinese Materia Medica of Chinese Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China.
⁴ Internal Medicine, University of Iowa, Iowa City, IA, USA.
⁵ Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090, Jette, Belgium.
⁶ The Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China. [email protected].
⁷ School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China. [email protected].
⁸ Key Laboratory for Combination of Acupuncture and Chinese Materia Medica of Chinese Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China. [email protected].
⁹ Internal Medicine, University of Iowa, Iowa City, IA, USA. [email protected].

^# Contributed equally.

PMID: 32901100
DOI: 10.1038/s41375-020-01033-z

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Bortezomib / pharmacology*
Case-Control Studies
Cell Proliferation
Cyclin-Dependent Kinase Inhibitor p27 / genetics
Cyclin-Dependent Kinase Inhibitor p27 / metabolism*
Drug Resistance, Neoplasm*
Gene Expression Regulation, Neoplastic / drug effects*
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / genetics
Multiple Myeloma / metabolism
Multiple Myeloma / pathology
Prognosis
Proteasome Inhibitors / pharmacology*
Survival Rate
Tumor Cells, Cultured
Ubiquitin-Protein Ligases / genetics
Ubiquitin-Protein Ligases / metabolism*
Ubiquitination

Substances

Antineoplastic Agents
CDKN1B protein, human
Proteasome Inhibitors
Cyclin-Dependent Kinase Inhibitor p27
Bortezomib
COP1 protein, human
Ubiquitin-Protein Ligases